Researchers tracking DNA methylation patterns in older adults found that daily multivitamin use slowed biological aging markers over two years. Participants taking the supplement showed aging reductions equivalent to approximately four months of reversed biological time, measured through epigenetic clock analysis. The effect proved strongest in participants whose biological age exceeded their chronological age at the study's start.
Epigenetic clocks measure chemical modifications to DNA that accumulate with age, offering a biological aging metric independent of calendar years. The study involved a large clinical trial with older adults as subjects, though the exact sample size and participant demographics remain unspecified in available details. Researchers observed consistent slowdowns across multiple epigenetic clock measures, suggesting a reproducible effect rather than chance variation.
The mechanism remains unclear. Multivitamins contain diverse micronutrients, making it difficult to isolate which components drive the observed benefit. B vitamins, antioxidants like vitamins C and E, and minerals such as zinc could each theoretically influence epigenetic aging pathways, but the trial did not isolate individual nutrients.
The findings carry important limitations. Two years represents a relatively short observation window for aging research. The study measured biological aging through computational models rather than direct health outcomes like disease incidence or mortality. Whether slower epigenetic aging translates to actual lifespan extension or reduced disease risk remains unproven. Additionally, the strongest benefits appeared in people already biologically older than their years, limiting generalizability to the broader population.
Previous research on multivitamins has produced mixed results. Some studies found no mortality benefit from routine supplementation in healthy adults, while others identified specific micronutrient deficiencies that warrant correction. This trial suggests multivitamins might benefit a specific subgroup rather than everyone equally.
The research opens questions about personalized supplementation strategies based on individual epigenetic aging profiles. Larger